Southampton, UK – 20 October 2008 – Innovative pharmaceutical company Karus Therapeutics Ltd has today announced that the company’s Chief Scientific Officer, Dr Stephen Shuttleworth, will be making a presentation at CHI’s Second Annual HDAC Inhibitors meeting in Boston, MA. This meeting is part of the Discovery on Target conference and brings together research and development teams from pharmaceutical and biotechnology companies that are active in the field of HDAC inhibitors.
Dr Shuttleworth’s talk, entitled “A new generation of HDAC inhibitors based on synthetically optimized natural products” will describe Karus’s best-in-class non-hydroxamate, nonbenzamide histone deacetylase inhibitors (HDIs) that have gold-standard potency and potent PD effects that confer high in vitro potency against a diverse range of tumour cell lines and in vivo models.
“We are delighted to be invited to present at this important event,” said Dr Shuttleworth. “Our approach in the HDAC inhibitor arena is distinct from that of our competitors’, and we are pleased to have the opportunity to disclose the important progress that we have made in our HDAC R&D programmes to date, and to outline our strategy for clinical development in the cancer and inflammatory disease settings.”
Karus is a pharmaceutical company with a mission to design, develop and partner innovative, best-in-class, molecular-targeted, small-molecule drugs to treat inflammation, immune disease and cancer. The company’s primary focus is the development of proprietary drugs that target epigenetic mechanisms and lipid kinase signaling. The outstanding potency and excellent tolerability of Karus’s HDAC inhibitors (HDI) represent an innovative approach to this important drug target and brings the promise of a new gold-standard in the treatment of rheumatoid arthritis, psoriasis and cancer.
Karus comprises a seasoned commercial and scientific team, with unrivalled experience in the biotechnology and pharmaceutical sector. This expertise has enabled the company to remain focused and to make efficient progress in its development programs. The company was formed in July 2005 to develop a new family of highly potent, optimized HDAC inhibitors that were identified at the University of Southampton and Cancer Research UK.